Joseph Nolan Email & Phone Number

Lake Forest, Il, Us

AveXis, Inc. is a clinical-stage gene therapy company, dedicated to developing and commercializing novel treatments for patients suffering from rare and life-threatening neurological genetic diseases. $4B plus in market cap, sold to Novartis for $8.7B on April 9, 2018.• Creating a strategy for the launch plan of AVXS-101, a proprietary gene therapy product• Designing an innovative approach to market access and pricing given the new market requirements of gene therapy, including a value-based outcomes plan and pay overtime model• Partnering on the development of a companion diagnostic test as well as fighting for newborn screening with advocacy to ensure superior outcomes/value• Building out the entire U.S. team in preparation for a launch• Generating life cycle management plans in the treatment of Rhett Disease and ALS

Directed startup companies on identification, design, and execution of value creation plans to launch products and drive growth. • Designed a strategic presentation for a pharmaceutical and companion device combination startup with a proposed valuation of $2B. Helping owners identify potential buyers and PE/VC; success achieved with the contract including upfront funding with potential $700M in valuation• Consulted for PE firm seeking investments in orphan space; successfully identified three potential investments with a forecasted return of six times the invested capital - $50M • Developed a personalized medicine business plan, a combination diagnostic and orphan biologic with a specific autoimmune response. Designed a business plan, resented and obtained early $4M investor and currently expanding the plan to raise an additional $20M for phase 2 trials• Currently advising Hong Kong-based investor interested in global pharma business investments. Three targets identified, due diligence underway; target price ranges from $50M to $250M

Milwaukee, Wi, Us

Guided success for $190M operation with 750+ employees spread over four primary business units (Patient Support, Compliance Services, Channel Support, and Technology Services). Full P&L responsibility with reporting to BOD, generating 23% profitability Year over Year. • Directed specialty pharmacy, sales, marketing, distribution and contracting• Developed strategy for market access, payer contracting, copay assistance and patient case management for specialty pharmacy services, exceeding 23% profitability target

Designed, developed and delivered a CNS business plan from the ground up to a business with a potential of $1B-$2B in revenue. Guided business development, asset acquisition and growth performance with a target of selling the company to more than $800M in shareholder value. • Recruited, trained and developed commercial and business development teams, maintaining full P&L responsibility, delivering results while staying under the allotted $5M annual budget • Developed strategy to position lead orphan compound in Duchene Muscular Dystrophy• Directed payer strategy and market access plan, including contracts with specialty pharma• Additionally, grew future revenue by $500M by leading business development acquisition

Valby, Copenhagen, Dk

Directed growth of Lundbeck’s new US affiliate (Ovation acquisition) to revenues of more than $1B, guiding growth in all commercial functions, including payer strategy, sales team performance, marketing strategy, and business development. Full P&L responsibility for 7 US assets portfolio.• Led the successful launch of 4 orphan assets with peak sales of $600M• Built, trained and managed 600+ employees to support 7 product launches including 4 of the specialty pharmacy, orphan space and 3 in the traditional retail setting• Successfully led the Board of Directors to execute on the acquisition of Chelsea Therapeutics, a product with peak sales targeted above $400M• Led orphan launch to first-year revenue of $50+M in Huntington’s, peak sales over $500M• Created and implemented growth strategy for specialty product portfolio, surpassing revenue goals, claiming 75% of Lundbeck’s growth in US annual revenue• Developed, negotiated and implemented the acquisition of products to enhance the company’s portfolio, adding $500M in assets and 30% increase in sales over a 2-year period

Tokyo, Jp

Guided focus, vision and global maximization of portfolio leading several large cross-functional teams in therapeutic areas of CNS and oncology. Directed annual portfolio assessment. • Designed and implemented a new portfolio assessment process, resulting in first year savings of over $130M through refining strategic focus and ROI• Directed two managers and two analysts during portfolio assessment process

Abbott Park, Illinois, Us

Complete P&L responsibility for $870M portfolio of generic and specialty injectables, including the management of revenue, R&D product selection, API, CMO, regulatory and global partnerships. • Exceeded growth targets by 15%. Generated incremental 5% growth through commercial execution of strategic partnerships• Championed an in-licensing collaboration deal, finalizing an agreement between Abbott International and a major European company, delivering worldwide peak sales of $1B+

Master Of Business Administration - Mba, Marketing

Bachelor Of Science - Bs, Finance, General